Bristol/AstraZeneca Demonstrate Safety In Dapagliflozin Study For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.
You may also be interested in...
Bristol/AstraZeneca Initiate Phase III Studies Of SGLT-2 Inhibitor Dapagliflozin
Drug is on track to become first-in-class treatment for type 2 diabetes.
Bristol/AstraZeneca Initiate Phase III Studies Of SGLT-2 Inhibitor Dapagliflozin
Drug is on track to become first-in-class treatment for type 2 diabetes.
Saxagliptin Plus Metformin Lowers HbA1C Levels Over Metformin Alone In Phase III Study
Data involving 743 patients is the first Phase III data evaluating the DDP-4 inhibitor to be released by Bristol/AstraZeneca.